AbbVie options integrin-based compounds from Morphic, paving way for potential fibrosis treatments
Almost two years after first inking a deal with AbbVie worth $100 million upfront, Morphic Therapeutic received another bit of good news from the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
